WallStSmart

Circle Internet Group, Inc. (CRCL)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 345% more annual revenue ($12.22B vs $2.75B). VRTX leads profitability with a 35.5% profit margin vs -2.5%. VRTX appears more attractively valued with a PEG of 2.10. VRTX earns a higher WallStSmart Score of 66/100 (B-).

CRCL

Hold

42

out of 100

Grade: D

Growth: 10.0Profit: 3.0Value: 4.0Quality: 5.0
Piotroski: 2/9Altman Z: 0.05

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CRCL.

VRTXUndervalued (+57.2%)

Margin of Safety

+57.2%

Fair Value

$992.87

Current Price

$429.82

$563.05 discount

UndervaluedFair: $992.87Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CRCL3 strengths · Avg: 10.0/10
Revenue GrowthGrowth
76.9%10/10

Revenue surging 76.9% year-over-year

EPS GrowthGrowth
880.0%10/10

Earnings expanding 880.0% YoY

Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$107.87B9/10

Large-cap with strong market position

Return on EquityProfitability
24.2%9/10

Every $100 of equity generates 24 in profit

Areas to Watch

CRCL4 concerns · Avg: 2.8/10
Price/BookValuation
8.3x4/10

Trading at 8.3x book value

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
4.352/10

Expensive relative to growth rate

Return on EquityProfitability
-2.8%2/10

ROE of -2.8% — below average capital efficiency

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.104/10

Expensive relative to growth rate

P/E RatioValuation
25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CRCL

The strongest argument for CRCL centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 76.9% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : CRCL

The primary concerns for CRCL are Price/Book, Piotroski F-Score, PEG Ratio.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

CRCL profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.

CRCL is growing revenue faster at 76.9% — sustainability is the question.

VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.

Monitor CAPITAL MARKETS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VRTX scores higher overall (66/100 vs 42/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Circle Internet Group, Inc.

FINANCIAL SERVICES · CAPITAL MARKETS · USA

Circle Internet Group, Inc. is a platform, network, and market infrastructure for stablecoin and blockchain applications. The company is headquartered in New York, New York.

Visit Website →

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?